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Abstract
Background: Synovial sarcoma is a high-grade malignant tumor of soft tissue, characterized by the
specific chromosomal translocation t(X;18), and its resultant SYT-SSX fusion gene. Despite
intensive multimodality therapy, the majority of metastatic or relapsed diseases still remain
incurable, thus suggesting a need for new therapeutic options. We previously demonstrated the
antigenicity of SYT-SSX gene-derived peptides by in vitro analyses. The present study was designed
to evaluate in vivo immunological property of a SYT-SSX junction peptide in selected patients with
synovial sarcoma.
Methods: A 9-mer peptide (SYT-SSX B: GYDQIMPKK) spanning the SYT-SSX fusion region was
synthesized. Eligible patients were those (i) who have histologically and genetically confirmed,
unresectable synovial sarcoma (SYT-SSX1 or SYT-SSX2 positive), (ii) HLA-A*2402 positive, (iii)
between 20 and 70 years old, (iv) ECOG performance status between 0 and 3, and (v) who gave
informed consent. Vaccinations with SYT-SSX B peptide (0.1 mg or 1.0 mg) were given
subcutaneously six times at 14-day intervals. These patients were evaluated for DTH skin test,
adverse events, tumor size, tetramer staining, and peptide-specific CTL induction.
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Results: A total of 16 vaccinations were carried out in six patients. The results were (i) no serious
adverse effects or DTH reactions, (ii) suppression of tumor progression in one patient, (iii)
increases in the frequency of peptide-specific CTLs in three patients and a decrease in one patient,
and (iv) successful induction of peptide-specific CTLs from four patients.
Conclusions: Our findings indicate the safety of the SYT-SSX junction peptide in the use of
vaccination and also give support to the property of the peptide to evoke in vivo immunological
responses. Modification of both the peptide itself and the related protocol is required to further
improve the therapeutic efficacy.
Background
Synovial sarcoma is a relatively rare, high-grade malignant
tumor of soft tissue, characterized by biphasic or
monophasic histology, specific chromosomal transloca-
tion t(X;18), and its resultant SYT-SSX fusion gene[1]. This
tumor affects mostly adolescents and young adults. The 5-
year survival rates of patients with this localized disease
have ranged from 66% to 80% in the current literature [2-
5]. However, the majority of metastatic or relapsed dis-
eases still remain incurable despite intensive multimodal-
ity therapy. Therefore there is a need for additional new
therapeutic options other than conventional surgery, radi-
otherapy, and chemotherapy.
Vaccination of tumor antigenic peptide serves as a com-
monly accepted method in anti-cancer immuno-
therapy[6,7]. This is based on the rationale that T cells
recognize antigenic peptide in the context of MHC mole-
cules on the tumor cell or antigen presenting cells through
the T cell receptor, which elicits subsequent anti-tumor
immune responses. Identification of antigenic peptides
recognized T cells enabled us to apply vaccination trials to
a variety of tumors, except bone and soft tissue
sarcomas[8].
Currently tumor specific chromosomal translocations are
defined in leukemias, lymphomas, and sarcomas[9,10].
The fusion regions of translocation products are specifi-
cally expressed by its corresponding tumors, thereby serv-
ing as targets of great potential for tumor specific
therapies, including immunotherapy[11,12]. We[13,14]
found that SYT-SSX fusion gene-derived peptides can be
recognized by circulating CD8+ T cells in patients with
synovial sarcoma and elicit HLA-restricted, tumor specific
cytotoxic responses by in vitro stimulations. In this study,
we conducted a phase I pilot trial of vaccination of a SYT-
SSX-derived junction peptide in elected synovial sarcoma
patients.
Methods
Peptide
A 9-mer peptide (SYT-SSX B: GYDQIMPKK) spanning the
SYT-SSX fusion region was synthesized under good man-
ufacturing practice (GMP) conditions by Multiple Peptide
Systems (San Diego, CA). The identity of the peptide was
confirmed by mass spectral analysis, and was shown to
have more than 98% purity when assessed by high pres-
sure liquid chromatography analysis. The peptide was
delivered us in the form of a freeze-dried, sterile white
powder. It was dissolved in 1.0 ml of physiological saline
(Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) and
stored at -80°C until just before usage. The affinity of the
peptide to HLA-A24 molecules and its antigenicity were
determined in previous studies[13,14].
Eligibility
The study protocol was approved by the Clinical Institu-
tional Ethical Review Board of the Medical Institute of
Bioregulation, Sapporo Medical University, Japan. Eligi-
ble patients were those (i) who have histologically and
genetically confirmed, unresectable synovial sarcoma
(SYT-SSX1 or SYT-SSX2 positive), (ii) HLA-A*2402 posi-
tive, (iii) between 20 and 70 years old, (iv) ECOG per-
formance status between 0 and 3, and (v) who gave
informed consent. Exclusion criteria included (i) prior
chemotherapy, steroid therapy, or other immunotherapy
within the past 4 weeks, (ii) presence of other cancers that
might influence the prognosis, (iii) immunodeficiency or
a history of splenectomy, (iv) severe cardiac insufficiency,
acute infection, or hematopoietic failure, (v) ongoing
breast-feeding, (vi) unsuitability for the trial based on the
clinical judgment of the doctors involved. This study was
carried out at the Department of Orthopaedic Surgery,
Sapporo Medical University Hospital from June 2003
until the end of September 2004.
Vaccination schedule
Vaccinations with SYT-SSX B peptide were administered
subcutaneously into the upper arm six times at 14-day
intervals. In order to set up a dose-escalation trial, the
patients were separated into the two groups. Each group
included three patients. Those from group 1 received 0.1
mg and group 2 participants received 1.0 mg.
Delayed-type hypersensitivity (DTH) skin test
Delayed-type hypersensitivity (DTH) skin test was per-
formed at each vaccination. The peptide (10 µg) solution
in physiological saline (0.1 ml) or physiological salineJournal of Translational Medicine 2005, 3:1 http://www.translational-medicine.com/content/3/1/1
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alone (0.1 ml) were separately injected intradermally into
the forearm. A positive reaction was defined as a diameter
of erythema of more than 4 mm, 48 hr after the injection.
Toxicity evaluation
Patients were examined closely for signs of toxicity during
and after vaccination. Adverse events were recorded using
the National Cancer Institute Common Toxicity Criteria
(NCI-CTC).
Clinical response evaluation
Physical examinations and hematological examinations
were monitored before and after each vaccination. Tumor
size was evaluated by computed tomography (CT) scans
before treatment, and again after three vaccinations, and
then at the end of the study period. A complete response
(CR) was defined as complete disappearance of all meas-
urable diseases. A partial response (PR) was defined as a
>= 50% decrease from the baseline in size of all measura-
ble lesions (sum of products of maximal perpendicular
diameters) lasting for a period of at least 4 weeks. Progres-
sive disease (PD) was defined as an increase in the sum of
the bi-dimensional measurements of all known disease
sites by at least 25% or by the appearance of new lesions.
No change (NC) was defined as the absence of matched
criteria for CR, PR, or PD.
Tetramer staining
HLA-A24/peptide tetramers (HLA-A24/B, HLA-A24/
R49.2, and HLA-A24/HIV) were previously constructed
[13-15]. Flowcytometric analysis was performed by taking
peripheral blood mononuclear cells (PBMCs) from
patients. PBMCs were taken at pre-vaccination and again
one week after 1st, 3rd, and 6th vaccination. Cells were
stained with PE-labeled tetramers at 37°C for 20 min and
a FITC-conjugated anti-CD8 mAb (Becton Dickinson) at
4°C for 30 min. Analysis of stained PBMCs was per-
formed using FACScan (Becton Dickinson) and CellQuest
software (Becton Dickinson). The frequency of CTL pre-
cursors was calculated as the number of tetramer positive
cells / the number of CD8+ cells.
CTL induction
Cytotoxic T lymphocytes (CTLs) were induced from the
PBMCs of patients using SYT-SSX B peptides according to
the method described before[13,14]. The cytotoxic activ-
ity was evaluated by 6-h 51Cr release assay[13]. As target
cells, synovial sarcoma cell lines (Fuji, HS-SY-II, and
SW982), an erythroleukemia cell line (K562), and a T-B
Lymphoblast hybrid transfected with HLA-A*2402 (T2-
A*2402) were used. Fuji and HS-SY-II were both HLA-A24
and SYT-SSX positive lines. SW982 and K562 were both
HLA-A24 and SYT-SSX negative lines used as controls. T2-
A*2402 cells were used to determine peptide-specific
cytotoxicity by pulsation with SYT-SSX B or HIV peptide
before labeling. The stimulated CD8+ T cells were mixed
with the labeled target cells. After a 6-h incubation period
at 37°C, the release of the 51Cr label was measured by col-
lecting the supernatant, followed by quantification in an
automated gamma counter. The percentage of specific
cytotoxicity was calculated as the percentage of specific
51Cr release: [(experimental 51Cr release - spontaneous
51Cr release) / (maximum 51Cr release - spontaneous 51Cr
release)] × 100. Maximum 51Cr release was measured by
incubating the labelled target cells with 2% NP-40,
instead of the stimulated CD8+ T cells. CTL induction was
determined as successful when specific cyotoxicity of 10%
or more was achieved on Fuji, HS-SY-II, and SYT-SSX B
peptide-pulsed T2-A*2402 cells.
Results
Patient profiles
Six patients were enrolled in the study (Table 1). There
were four men and two women with an average age of
34.7 years old (range 21–69 years). All patients had mul-
tiple metastatic lesions of the lung. A six-time vaccination
schedule was completed in three patients, while the
remaining three discontinued the vaccination regimen
because of rapid disease progression. None of the treat-
ment interruptions were due to the adverse effects of the
Table 1: Profiles of participants and clinical resoponses
Patient no. Age Gender Dose of peptide (mg) Number of vaccination Adverse events DTH skin test Evaluation of CT images
16 9 M 0 . 1 1 - - P D
23 2 M 0 . 1 3 - - P D
32 1 F 0 . 1 6 - - P D
42 1 M 1 . 0 6 - - P D
5 39 F 1.0 6 Fever - NC
62 6 M 1 . 0 4 - - P D
PD: progressive disease, NC: no changeJournal of Translational Medicine 2005, 3:1 http://www.translational-medicine.com/content/3/1/1
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vaccination.
Safety and DTH skin test
One patient (case 5) experienced slight fever (grade 1)
after the first vaccination. No other adverse events were
observed during vaccination. DTH skin test was per-
formed at each vaccination and assessed 48 hr later. Reac-
tions were determined as negative in all patients.
Clinical response
Recognized disease progression occurred in five out of six
patients during the vaccination period (Table 1, Fig. 1). In
contrast, one patient (case 5) showed no such rapid pro-
gression (Table 1, Fig. 2). These patients, except in case 1,
had received systemic multidrug chemotherapy from one
to four months before enrolling on this study.
Tetramer analysis and CTL induction
Peptide-specific immunological responses were evaluated
in five patients by using HLA-A24/peptide tetramer analy-
sis and in vitro CTL induction. As determined by flowcy-
tometric analysis using HLA/peptide tetramers (Table 2),
frequencies of CTLs specific for SYT-SSX B peptide were
shown to be at background levels (less than 0.1%) in
three patients prior to vaccination. Those frequencies
increased after the first (cases 4 and 6) and the third vac-
cination (case 2) (Fig. 3). In the remaining two patients
(cases 3 and 5), SYT-SSX B peptide-specific CTLs existed
beyond the background levels before vaccination. Of
these, B peptide-specific CTL frequencies increased
slightly in case 2 upon a series of vaccinations. On the
contrary, the CTL frequencies in peripheral blood
decreased to the background level after the third vaccina-
tion in case 5, whose metastatic diseases remained stable
during the vaccination period. For comparison, tetramers
with irrelevant peptides were constructed as internal con-
trols and utilized in four patients. Notably, CTL frequen-
cies reacting to those irrelevant tetramers remained under
the background level during the course of vaccinations in
all patients.
Table 3 depicts the results of CTL induction by in vitro
stimulations with SYT-SSX B peptide. Before vaccination,
CTLs specific for SYT-SSX B peptide were successfully
induced from one patient (case 2) who showed a high fre-
quency of CTL precursors. After the first or third vaccina-
tion, CTLs were induced from four of five patients. Figure
4 represents the results of cytotoxicity assay. As shown,
CTLs induced from the case 4 patient exhibited cytotoxic
activities against T2-A*2402 cells pulsed with SYT-SSX B
peptide, and synovial sarcoma cell lines expressing HLA-
A24 and SYT-SSX (Fuji and HS-SY-II) in various effecter/
target ratios examined. In contrast, the cytotoxity was less
than 10% against T2-A*2402 cells without peptide pulsa-
tion, those pulsed with irrelevant HIV peptide, and tumor
cells lacking HLA-A24 and SYT-SSX (SW982 and K562).
These findings suggest that induction of peptide-specific
CT scan image of the lung of case 3 patient Figure 1
CT scan image of the lung of case 3 patient. A: Before vaccination (May 15, 2003). B: After the third vaccination (June 18, 
2003). Rapid growth of the metastatic tumors and pleural effusion were seen.
ABJournal of Translational Medicine 2005, 3:1 http://www.translational-medicine.com/content/3/1/1
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immune responses in patients with synovial sarcoma,
who received the SYT-SSX junction peptide vaccine.
Discussion
The present study was designed to evaluate the in vivo
immunological property of a 9-mer SYT-SSX junction
peptide in patients with disseminated synovial sarcoma. A
total of 16 vaccinations of the peptide in six patients
revealed (i) no serious adverse effects in any case, (ii)
suppression of tumor progression in one patient, (iii)
increases in the frequency of peptide-specific CTLs in
three patients and a decrease in one patient, and (iv)
CT scan image of the lung of case 5 patient Figure 2
CT scan image of the lung of case 5 patient. A: Before vaccination (July 8, 2003). B: After the first vaccination (July 22, 2003). C: 
After the third vaccination (August 19, 2003). D: After the sixth vaccination (September 16, 2003). The metastatic tumors 
appeared to be dormant after the first vaccination.
Table 2: HLA-A24/peptide tetramer analysis
case Pre-vaccination After 1st vac. After 3rd vac. After 6th vac.
2 0.02/N.D 0.02/N.D 3.05/N.D N.D
3 0.42/0.02* 0.49/0.02 0.52/0.02 0.62/0.01
4 0.06/0.01 0.41/0.00 0.36/0.01 0.47/0.01
5 0.50/0.06 0.52/0.01 0.09/0.00 0.03/0.02
6 0.02/0.01 0.15/0.01 0.08/0.00 N.D
N.D: not determined, *B peptide tetramer / Control peptide tetramer
HLA-A24/R49.2 pepitde tetramer was used as control in the case 3 patient.
HLA-A24/HIV pepitde tetramer was used as control in the other patients.
A B
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Frequency of CTLs analyzed by HLA-A24/peptide tetramers in the case 4 patient Figure 3
Frequency of CTLs analyzed by HLA-A24/peptide tetramers in the case 4 patient. Frequencies of each analysis were described 
in Table 2.
Table 3: Induction of peptide specific CTLs
case Pre-vaccination After 1st vac. After 3rd vac. After 6th vac.
2 Failure Failure Success N.D
3 Success Success Success Failure
4 Failure Success Success N.D
5 Failure Success Failure Failure
6 Failure Failure Failure N.D
N.D: not determined
Before vaccination After first vaccination After sixth vaccination
H I V
t e t r
a m e r
SYT- SS
X
B
t e
t r
a m e r
0.06 0.41 0.47
0.01 0.00 0.01Journal of Translational Medicine 2005, 3:1 http://www.translational-medicine.com/content/3/1/1
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successful induction of peptide-specific CTLs from four
patients. These findings suggest that the SYT-SSX junction
peptide is safe to use as a vaccine and also has the property
to evoke in vivo immunological responses.
With respect to the clinical efficacy, none of the enrolled
patients showed signs of tumor remission. However, in
the case 5 patient, tumors showed some dormancy during
the vaccination period, in comparison to the other five
patients in whom tumors grew rapidly from the early
phase of the regimen. The case 5 patient had received one
cycle of systemic chemotherapy four months before
enrollment, making the possibility of residual chemother-
apeutic efficacy unlikely. The other five patients, except in
case 1, had received systemic chemotherapy one to two
months before perticipation. Notably, frequency of circu-
lating peptide-specific CTLs decreased in the case 5
patient, while CTL frequencies remained unchanged or
increased significantly in the other four patients exam-
ined. Decrease in circulating CTLs in the case 5 patient
may have resulted from accumulation of CTLs at the
tumor sites, although biopsy of the tumors was not
performed.
Vaccination trials of fusion gene-derived peptides have
been reported with BCR-ABL in 12 patients with chronic
myelogenous leukemia[16], EWS-FLI1 in 12 patients with
Ewing's sarcoma[17], and PAX3-FKHR in four patients
Cytotoxicity of CTLs induced from the case 4 patient Figure 4
Cytotoxicity of CTLs induced from the case 4 patient. T2-P(-): T2-A*2402 cells without peptide pulsation, T2-B: T2-A*2402 
cells pulsed with SYT-SSX B peptide, T2-HIV: T2-A*2402 cells pulsed with HIV peptide. Specific cytotoxicity was observed 
against T2-A*2402 cells pulsed with SYT-SSX B peptide, and synovial sarcoma cell lines expressing HLA-A24 and SYT-SSX (Fuji 
and HS-SY-II). E/T: Effecter cells/target cells ratio.
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with alveolar rhabdomyosarcoma[17]. In addition, Mat-
suzaki et al.[18] reported a case of a synovial sarcoma
patient who were treated with autologous dendritic cells
pulsed with a mixture of SYT-SSX junction peptides (8–16
mer). In these studies, tumor remission was noted only in
one patient with Ewing's sarcoma where IL-2 was con-
comitantly administered. These findings together with the
results of our present trial have indicated the limited ther-
apeutic efficacy of natural junction peptides. In this
regard, we discovered improved in vitro immunogenicity
of the SYT-SSX junction peptide by the substitution of an
HLA-A24 anchor residue (position 9)[14]. Clinical study
of this anchor-substituted peptide is currently underway.
Besides modification of the peptide itself, concurrent use
of adjuvants and cytokines, and adoptive T cell or/and
dendritic transfer should further improve the therapeutic
efficacy[8,19]. Also, it is important to determine the
appropriate timing of vaccination and proper endpoints
of clinical studies.
To monitor the immunological responses, we used HLA/
peptide tetramer and in vitro CTL induction. Other mon-
itoring procedures such as ELISPOT assay should provide
further information. Nevertheless, the use of an internal
control tetramer with HIV peptide added strength in this
present comparative analysis. As shown in Table 2 and
Fig. 4, reactivity of circulating T cells to HIV peptide
tetramer remained under the background level through-
out the vaccination period.
Due to the rarity and highly malignant nature of synovial
sarcoma, three out of six patients failed to complete the
six-time vaccination regimen. Such difficulty in continua-
tion of vaccination has also been found in a trial of
patients with Ewing's sarcoma and alveolar rhabdomy-
osarcoma[17]. Another limitation in the current study is
lack of analysis on immunological significance of SYT-SSX
variants (SYT-SSX1 and SYT-SSX2). This question should
be addressed in a larger scale analysis.
Conclusions
This is the first clinical trial of SYT-SSX fusion gene-
derived peptide in patients with synovial sarcoma. The
present trial demonstrated the safety and immunogenic
property of the peptide. Modification of both the peptide
itself and the related protocol is required to further
improve the therapeutic efficacy.
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